Fondazione Italiana Linfomi - Ets
Clinical trials sponsored by Fondazione Italiana Linfomi - Ets, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Rare heart cancer under the microscope: italian study seeks answers Results expected Oct 2026 (estimated)
- Elderly lymphoma Patients' Well-Being under the microscope Results expected Dec 2026 (estimated)
- Scientists dig deeper into follicular lymphoma genes Results expected Dec 2026 (estimated)
- Italian study tracks Real-World use of zanubrutinib for rare blood cancer Results expected Dec 2026 (estimated)
- New combo aims to boost transplant success in Hodgkin's lymphoma Results expected Dec 2026 (estimated)
-
Radioactive antibody vs stem cell transplant: which keeps lymphoma at bay?
Disease control CompletedThis phase III trial compares two consolidation treatments for people with relapsed or refractory follicular lymphoma whose cancer has shrunk after chemotherapy. Participants receive either a radioactive antibody called Zevalin or high-dose chemotherapy followed by an autologous …
Phase 3 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo shows promise for rare blood cancer in early trial
Disease control CompletedThis study tests adding the drug romidepsin to standard chemotherapy (CHOEP) for young adults (ages 18-65) with a rare type of lymphoma called peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective before patients undergo a stem cell transplant. …
Phase 1/2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Real-World study confirms Mogamulizumab's effectiveness against rare skin cancer
Disease control CompletedThis study looked at 100 adults with cutaneous T-cell lymphoma (a rare type of skin cancer) who had already tried at least one other treatment. Researchers wanted to see how well the drug mogamulizumab works in everyday medical practice, not just in controlled trials. They measur…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising combo targets tough lymphoma in seniors
Disease control CompletedThis study tested whether adding the targeted drug venetoclax to standard chemotherapy (R-BAC) helps older patients with high-risk mantle cell lymphoma. 141 patients received the combination, aiming to improve how long they stay cancer-free. The approach is designed for those who…
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Pee and blood may spare patients painful bone marrow needles
Knowledge-focused CompletedThis study looked at 300 people with Waldenström's macroglobulinemia or a related condition to see if blood or urine tests could detect key genetic mutations as accurately as bone marrow biopsies. The goal is to find a less invasive way to monitor the disease over time. Researche…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
PET scans may sharpen staging for rare lymphoma
Knowledge-focused CompletedThis study examined whether PET scans can help doctors better stage mantle cell lymphoma and predict how patients will fare, compared to standard CT scans and bone marrow biopsies. Researchers analyzed data from 200 patients who had already completed a clinical trial. The goal wa…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
633 PMBCL patients studied: key insights on refractory disease and survival
Knowledge-focused CompletedThis study looked back at 633 people with primary mediastinal large B-cell lymphoma (PMBCL) treated in Italy between 2007 and 2019. Researchers collected data on how well treatments worked, how many patients had disease that didn't respond or came back early, and survival rates. …
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Chemo heart risk under the microscope in lymphoma patients
Knowledge-focused CompletedThis study followed 127 people with diffuse large B-cell lymphoma who were treated with a common chemotherapy regimen called R-CHOP. The main goal was to track how often heart problems occurred as a side effect of the treatment. Researchers also looked at how well the cancer resp…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC